4.5 Article

RNAi suppression of rice endogenous storage proteins enhances the production of rice-based Botulinum neutrotoxin type A vaccine

Journal

VACCINE
Volume 30, Issue 28, Pages 4160-4166

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2012.04.064

Keywords

Rice; Nasal vaccine; MucoRice; RNAi; Botulinum neutrotoxin

Funding

  1. Programs of Special Coordination Funds for Promoting Science and Technology
  2. Ministry of Education, Culture, Sports, Science, and Technology of Japan
  3. Core Research of Evolutional Science Technology (CREST) of the Japan Science and Technology Agency (JST)
  4. New Energy and Industrial Technology Development Organization (NEDO)
  5. Japan Society for the Promotion of Science (JSPS)
  6. Global Center of Excellence Program Center of Education and Research for Advanced Genome-Based Medicine For Personalized Medicine and the Control of Worldwide infectious Diseases
  7. Japan Foundation for Pediatric Research

Ask authors/readers for more resources

Mucosal vaccines based on rice (MucoRice) offer a highly practical and cost-effective strategy for vaccinating large populations against mucosal infections. However, the limitation of low expression and yield of vaccine antigens with high molecular weight remains to be overcome. Here, we introduced RNAi technology to advance the MucoRice system by co-introducing antisense sequences specific for genes encoding endogenous rice storage proteins to minimize storage protein production and allow more space for the accumulation of vaccine antigen in rice seed. When we used RNAi suppression of a combination of major rice endogenous storage proteins, 13 kDa prolamin and glutelin A in a T-DNA vector, we could highly express a vaccine comprising the 45 kDa C-terminal half of the heavy chain of botulinum type A neurotoxin (BoHc), at an average of 100 mu g per seed (MucoRice-BoHc). The MucoRice-Hc was water soluble, and was expressed in the cytoplasm but not in protein body I or II of rice seeds. Thus, our adaptation of the RNAi system improved the yield of a vaccine antigen with a high molecular weight. When the mucosal immunogenicity of the purified MucoRice-BoHc was examined, the vaccine induced protective immunity against a challenge with botulinum type A neurotoxin in mice. These findings demonstrate the efficiency and utility of the advanced MucoRice system as an innovative vaccine production system for generating highly immunogenic mucosal vaccines of high-molecular-weight antigens. (C) 2012 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available